Prasugrel Thienopyridine Derivative HCV RNA Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Hepatitis C, such as combination therapy with pegylated interferon and ribavirin, face challenges like limited efficacy, toxicity, and patient compliance issues, particularly in patients with cirrhosis or HCV genotype 1 infections, necessitating new therapeutic approaches that target the virus effectively while minimizing side effects and improving sustained virologic response rates.
Innovation Solution
Administration of the thienopyridine derivative prasugrel alone or in combination with anti-Hepatitis C drugs to treat Hepatitis C, leveraging its ability to inhibit platelet activation and aggregation, thereby modulating viral infection and offering improved safety and compliance.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If combination therapy with pegylated interferon and ribavirin is used to treat Hepatitis C, then antiviral efficacy is achieved, but toxicity and side effects increase
Solution Approach 1:
The patent extracts and isolates the essential antiviral function from the complex interferon-ribavirin combination, using only prasugrel to achieve HCV RNA reduction. This eliminates the toxic components (interferon and ribavirin) while retaining the therapeutic effect through selective inhibition of platelet activation and aggregation pathways critical for HCV replication.
Solution Approach 2:
The patent employs prasugrel, a short-acting thienopyridine derivative, as a temporary intervention to disrupt the HCV life cycle. The drug provides sufficient antiviral activity during the treatment period to reduce HCV RNA levels, after which its effects diminish, allowing for potential treatment cycles with minimal long-term toxicity accumulation.
2Ease of manufacture
If standard combination therapy is administered to patients with cirrhosis or HCV genotype 1, then treatment is provided, but patient compliance deteriorates due to toxicity and limited efficacy
Solution Approach 1:
The patent removes the compliance-barrier components (interferon injections and ribavirin side effects) from the treatment regimen, retaining only the oral prasugrel administration. This extraction of toxic elements while preserving antiviral activity directly addresses the compliance issues in difficult-to-treat populations.
Solution Approach 2:
The patent changes the treatment parameters from a complex multi-drug regimen requiring frequent monitoring to a simplified prasugrel-based therapy. This parameter change reduces treatment burden, improves quality of life, and enhances compliance particularly in patients with cirrhosis or genotype 1 infections who previously had poor outcomes.
3Quantity of substance
If nanosizing of prasugrel is implemented, then bioavailability is enhanced, but manufacturing complexity increases
Solution Approach 1:
The patent applies nanosizing technology to change the physical parameter of prasugrel particles, reducing them to nanoscale dimensions. This parameter change dramatically increases the surface area to volume ratio, enhancing dissolution rate and bioavailability. The manufacturing complexity increase is offset by the significant therapeutic benefit and potential dose reduction.
Solution Approach 2:
The patent employs composite nanomaterial formulations of prasugrel, combining the active pharmaceutical ingredient with nanocarrier materials or surface modifiers. These composite structures enhance bioavailability through improved solubility, stability, and cellular uptake, while the composite nature allows for controlled release and targeted delivery, justifying the increased manufacturing complexity.
Data Source
AI summary
The present invention relates to methods of treatment of hepatitis C using prasugrel. The methods of the present invention can be used in patients with hepatitis C administering prasugrel in combination with one or more anti-hepatitis C drugs.